2026-02-03 09:33:58,039 - replication - DEBUG - [core.utils] File logging configured: ./data/original/8/data-only/_log/extract.log
2026-02-03 09:33:58,040 - replication - INFO - Running Stage 1: original study extraction
2026-02-03 09:36:13,915 - replication - INFO - === GENERATED PROMPT (Stage 1) ===
You are an information extraction assistant tasked with filling out a structured JSON template based on research documents.

You will be provided with:
1. A JSON template where each key contains a description of what is expected
2. The original paper manuscript (original_paper.pdf)
3. Initial details file (initial_details_easy.txt) containing:
   - Claim statement (use this directly, do not extract from paper)
   - Hypotheses (use these directly, do not extract from paper)

Your goal is to:
- For 'claim.statement' field: Use the exact statement from initial_details_easy.txt
- For 'hypotheses' field: Use the exact list from initial_details_easy.txt
- For all other fields: Extract content only from original_paper.pdf
- Leave fields as `not stated` if information isn't found in the designated source

Output Requirements:
- Return a valid JSON object only.
- Do NOT wrap the output in markdown (no ```json).
- Do NOT include extra text, commentary, or notes.

Begin extraction using the provided schema below and the file contents. Ensure accuracy and completeness.
- Strictly use provided sources as specified.

Here is the JSON template, and its values represent descriptions of what is expected to be stored in each key:

{
  "original_study": {
    "claim": {
      "hypotheses": "A testable hypothesis based on the claim",
      "hypotheses_location": "Specific location where the hypotheses is stated in the original paper",
      "statement": "The main claim made by the original study that matches the claim given as an input.",
      "statement_location": "Specific location where the claim is stated in the original paper.",
      "study_type": "Type of study (Experimental, Observational, Meta-Analysis)"
    },
    "data": {
      "source": "Data Source (e.g., survey, database)",
      "wave_or_subset": "Specific waves or subsets (if applicable)",
      "sample_size": "Sample size of the selected data (if applicable)",
      "unit_of_analysis": "Unit of analysis (e.g., individual, household)",
      "access_details": "Access details (e.g., restrictions, request process)",
      "notes": "Any additional information or caveats (e.g., encoding issues, nested structure, missing metadata, unusual column formats)"
    },
    "method": {
      "description": "Narrative summary of how the study was conducted.",
      "steps": "Ordered list of procedural steps to reproduce the study.",
      "models": "Models or statistical approach (e.g., regression type)",
      "outcome_variable": "Dependent/outcome variable measured or analyzed",
      "independent_variables": "Primary variables expected to influence the outcome",
      "control_variables": "Variables controlled for in the analysis",
      "tools_software": "Tools or software specifics (e.g., mentions of R, Python, packages)"
    },
    "results": {
      "summary": "Narrative summary of the main results or findings from the original study.",
      "numerical_results": [
        {
          "outcome_name": "Name or label of the outcome (e.g., 'test_score', 'conversion_rate')",
          "value": "Numeric result value (e.g., 0.45)",
          "unit": "Optional unit of measurement (e.g., %, points, ms)",
          "effect_size": "Optional effect size (e.g., Cohen's d, odds ratio)",
          "confidence_interval": {
            "lower": "Lower bound (e.g., 0.32)",
            "upper": "Upper bound (e.g., 0.58)",
            "level": "Confidence level, e.g., 95"
          },
          "p_value": "Optional p-value associated with the result (e.g., 0.001)",
          "statistical_significance": "Boolean indicating if result is statistically significant",
          "direction": "Qualitative direction of the effect (positive, negative, or null) based on the sign and magnitude of the reported result."
        }
      ]
    },
    "metadata": {
      "original_paper_id": "DOI or unique identifier.",
      "original_paper_title": "Title of the original paper.",
      "original_paper_code": "Link to the original study's codebase.",
      "original_paper_data": "Link to the original study's dataset(s)."
    }
  }
}

Please return only a completed JSON object appropriate for this stage.
2026-02-03 09:36:13,923 - replication - INFO - 

=== GENERATED MESSAGE (Stage 1) ===
Extract stage 1 (original study) information.

You are tasked with extracting structured information from the following text based on the given instructions.

=== START OF FILE CONTENT ===

---
**original_paper.pdf**
--- PDF SUMMARY (Document was 38 pages long) ---
The document was too long to read directly, so here is a detailed summary of all sections:

The paper "Price Subsidies, Diagnostic Tests, and Targeting of Malaria Treatment: Evidence from a Randomized Controlled Trial" by Jessica Cohen, Pascaline Dupas, and Simone Schaner investigates the issue of under- and over-treatment of malaria in Kenya through a randomized controlled trial. The trial focuses on the implications of subsidizing antimalarials and explores two strategies to improve targeted drug delivery: reducing subsidy levels and introducing rapid diagnostic tests (RDTs) over-the-counter.

Key methodologies include substantiating household treatment-seeking behaviors in Kenya with experimental data, and introducing random variations in access to subsidized ACTs (artemisinin combination therapies) and RDTs across over 2,700 households in Western Kenya.

The study yields five main empirical results:

1. **Procurement Behavior:** Many households prefer drug shops over public health systems for medication, with a 92% subsidy on ACTs resulting in more than doubling the treatment share from 19% to 41%.

2. **Targeting and Over-Treatment:** While access increased, targeting was poor, with only 56% of subsidized ACTs going to malaria-positive individuals. Over-treatment was notably significant among teens and adults (79% of adults taking ACTs did not actually have malaria).

3. **Subsidy Levels and Targeting Trade-off:** Reducing subsidy levels (from 92% to 80%) improved targeting from 56% to 75% while maintaining access for children. Adults often opted for cheaper antimalarials unless ACTs were available at the highest subsidy levels.

4. **RDT Availability:** Subsidizing RDTs doubled testing rates, yet over half of patients with negative results still opted for ACTs, highlighting a compliance issue.

5. **Short-term Effects of RDTs:** While retail sector RDTs did not immediately resolve over-treatment, the study suggests that compliance with test results might improve over time as households become more familiar with RDT reliability.

The study concludes that while subsidies improve access, they do not effectively ensure appropriate targeting, particularly among adults. Lowering subsidies helps improve targeting without substantially reducing access for high-risk groups like children. Introducing RDTs does increase testing but does not immediately rectify over-treatment, indicating the need for long-term strategies and education to enhance compliance.

The document discusses the impact of subsidies on malaria treatment access and resistance, focusing on the Affordable Medicines Facility for malaria (AMFm) initiative. The AMFm, launched in 2009, aimed to reduce the cost and increase the availability of Artemisinin-based Combination Therapies (ACTs) in retail sectors across seven pilot countries through a 95% subsidy to wholesalers. This initiative was costly, with over $450 million spent on drug copayments in just two years.

Critics argued the AMFm failed to save lives of the vulnerable or delay drug resistance, incentivizing medicine sales without diagnosis and not adequately serving poor populations, leading to its integration into the core Global Fund grant facility by 2014. Countries could then choose to subsidize retail ACTs using malaria control resources, impacting funds for other initiatives like bednets and spraying.

The paper provides insights for countries on allocating malaria control resources, finding an AMFm-type subsidy boosts access among malaria-positive poor without significantly crowding out public sector care. High over-treatment levels at the original subsidy suggest that reducing the subsidy could maintain benefits while lowering over-treatment and costs. The results are applicable to regions in East Africa with similar healthcare environments.

The study contributes to understanding under-diagnosis and over-treatment, major constraints in healthcare cost management, and treatment-seeking behaviors in resource-limited settings. It emphasizes the importance of balancing ACT accessibility with accurate targeting to reduce inappropriate use and improve social welfare through reduced under- and over-treatment.

The document explores the decision-making framework for malaria treatment, specifically looking at how subsidies for anti-malaria medication (ACT) and rapid diagnostic tests (RDTs) affect treatment choices. It uses a model where the value of action (either seeking treatment at a health center, drug shop, or doing nothing) depends on the perceived probability of having malaria. Households are assumed to have accurate subjective assessments of this probability.

Key methodologies include theoretical modeling of treatment decisions and simulations of different subsidy scenarios. The value of actions, denoted as \( V_a(\pi) \), considers both utility and cost, depending on the true malaria status (positive or negative). The study assumes that doing nothing becomes less attractive as the probability of malaria increases.

The study is illustrated using theoretical models presented in Figure 1, showcasing different scenarios: without subsidies, with ACT subsidies, and with RDT subsidies. These scenarios explain how subsidies can shift the preferred treatment option depending on the malaria probability.

Results from the study suggest:
1. Without subsidies, individuals opt for drug shop ACTs at higher malaria probabilities.
2. ACT subsidies increase access to ACTs but may decrease targeting accuracy, as more people buy ACTs from drug shops regardless of actual need.
3. RDT subsidies can decrease both under-treatment and over-treatment, as they help individuals make more informed decisions based on test results.

Two potential impacts of subsidies were identified:
- **ACT Subsidy:** Increases access but risks decreasing treatment targeting if individuals take ACTs when they might not have malaria.
- **RDT Subsidy:** May decrease inappropriate ACT use by guiding treatment with test results, although effectiveness depends on compliance with test outcomes.

The analysis underscores the importance of considering distributional impacts of subsidies, suggesting they could improve targeting if they increase access among high-risk groups previously unable to afford treatment.

The experimental design involved administering surveys and distributing vouchers for ACTs and RDTs in rural Kenyan districts, with data collected on treatment-seeking behavior from over 2,789 households. This design sought to measure access and targeting under various subsidy policies, emphasizing the importance of detailed illness-level data.

In conclusion, the study finds that while ACT subsidies can improve access, combining them with RDT subsidies offers a potential strategy to enhance treatment precision without exacerbating over-treatment, crucial for resource-constrained settings.

The study investigates the effectiveness and targeting of antimalarial subsidies in Kenya, particularly focusing on the affordable medicine facility for malaria (AMFm) pilot program. The experimental design involved random assignment of households into three treatment groups to simulate different subsidy levels and their effects on the purchase of artemisinin-based combination therapies (ACTs) and rapid diagnostic tests (RDTs) for malaria. The core groups were: 

1. No subsidy, where ACTs were purchased at the full market price.
2. ACT-only subsidy, with varied subsidy levels (92%, 88%, and 80%).
3. ACT+RDT subsidy, including the same ACT subsidies plus RDT availability, with RDTs either free or subsidized at 85% with or without refund options contingent on test results.

Key methodologies involved stratified random sampling based on proximity to drug shops and presence of children in households. The study utilized a surprise RDT offer to assess malaria positivity among ACT purchasers without RDT selection bias. The results showed no significant differences in RDT uptake across different subsidy arms, suggesting limited willingness to pay for RDTs despite subsidies. The randomization checks ensured statistical balance across treatment groups, confirming appropriate random assignment.

Educational levels, distance to health facilities, and initial awareness of ACTs or RDTs were assessed at baseline. Results indicated no significant differences regarding household characteristics across treatment groups, underscoring balanced baseline conditions.

In conclusion, the study reveals critical insights into subsidy impacts and consumer behavior regarding ACTs and RDTs. It highlights the persistent challenges in balancing drug access and appropriate use amidst imperfect information on malaria status. Despite extensive subsidy offers, the uptake of RDTs remained largely unaffected by price reductions, stressing the importance of convenience and accessibility over cost factors in consumer health-seeking behaviors. Data analysis was performed with considerations of false discovery rate adjustments, ensuring robustness and reliability of results.

The document is a technical paper analyzing the impacts of retail sector subsidies for ACTs (artemisinin-based combination therapies) on malaria treatment. The methodology includes collecting data through various means: administrative data from drug shop transactions, an endline survey conducted with households, and a symptoms database that predicts malaria positivity.

Key variables include:
- **Acres of Land:** Households had an average of 2.72 acres with significant negative effects when subsidized (-0.660**).
- **Distance from Drug Shops/Clinics:** Baseline of 1.68 km from drug shops and 6.57 km from clinics with minor or no significant changes in distance-related behavior.
- **Baseline Malaria Knowledge and Health Practices:** Various health metrics were probed, such as the number of bednets and knowledge of antimalarials, showing mostly non-significant impacts post-subsidy, except for some like a slight increase in RDT awareness (0.039) and the propensity to treat water.

Data was analyzed to address treatment-seeking behaviors and other metrics:
- **Administrative Data:** Data was captured from over 1,700 drug shop visits. This data was enriched by trained surveyors capturing details of medicines procured and clinical status via Rapid Diagnostic Tests (RDTs).
- **Endline Survey:** Conducted about four months after initial intervention with very little attrition (5%). It captured detailed household responses and illness episodes, ensuring coverage of at least one episode in most households.
- **Symptoms Database:** Used to predict malaria positivity through correlation with actual RDT results (0.48 correlation), lending confidence to the relative measure of suspected malaria conditions.

Results highlight age as a significant factor in malaria risk, with younger individuals (under 5 years) showing higher positivity (54%) compared to adults (14%). This age gradient is consistent with prior literature. The subsidy program analysis concluded:
- **Increased Access to ACTs:** Improvements in access to these treatments were noted, but specifics regarding direct impacts (under-treatment and over-treatment) weren't quantifiable due to logistic constraints.
- **Private Information Usage:** Households displayed advantageous selection due to private knowledge of malaria risk, impacting treatment-seeking behavior.

The paper concludes with plans to extend findings to wider discussions on cost-effectiveness by plugging in outcome predictions into broader treatment metrics like under-treatment and over-treatment rates. The goal is to assess alternative subsidy regimes, particularly focusing on age-focused targeting to enhance cost-effectiveness.

The technical paper examines the impact of varying subsidy levels for Artemisinin-based Combination Therapies (ACTs) on treatment-seeking behavior and access to ACTs. The study uses data from households experiencing first illness episodes during a specified study period. The analysis excludes households involved in Rapid Diagnostic Test (RDT) subsidies to isolate the effect of ACT subsidies.

**Methodologies:**
1. **Data Structure:** Data includes different levels of subsidies (92%, 88%, and 80%) compared against a control group with no subsidy.
2. **Statistical Analysis:** The study uses regression models with robust standard errors clustered at the household level. The effects are controlled for household head age and stratified by fixed effects.
3. **Target Group:** First illness episodes of households were analyzed, with separate attention to concurrent episodes but clustered at the household level.

**Results:**
1. **ACT Access:** All subsidy levels increase ACT access significantly. The control group had a 19% ACT access rate, while subsidies raised this by 16-23 percentage points, translating to an 85–118% increase (statistically significant at the 1% level).
2. **Treatment-Seeking Behavior:** Subsidies resulted in a 32% increase in visits to drug shops, and a reduction in the percentage of households seeking no care by 9–11 percentage points (~42%).
3. **Impact on Care Channels:** The increase in ACT access was primarily through drug shops, not health centers, and did not significantly affect malaria testing frequency.
4. **Antibiotic Use:** ACT subsidies reduced the share of antibiotic use in illness episodes, though the study had limited capacity to judge the appropriateness of this change.
5. **Subsidy Level Effects:** No statistically significant differences were found between different subsidy levels in their impact, suggesting similar effects across 80%, 88%, and 92% subsidies.

**Conclusions:**
- Subsidies substantially increased ACTs uptake without decreasing malaria testing rates and showed beneficial targeting, particularly at lower subsidy levels.
- The highest subsidy level (92%) had a lower malaria positivity rate among ACT takers, suggesting mistargeting versus the 88% and 80% subsidies.
- The paper emphasizes the importance of subsidy level selection to ensure effective malaria targeting while increasing ACT access.

Overall, ACT subsidies in the retail sector significantly improve treatment with minimal observable differences among various subsidy levels, leading to better targeting outcomes for lower subsidy levels.

The study examines the impact of antimalarial (ACT) subsidy levels and the addition of rapid diagnostic test (RDT) subsidies on ACT targeting, particularly the behavior of households in purchasing ACTs. Two primary mechanisms are explored: selection of different households into accessing ACTs and within-household selection based on probability of malaria positivity. Notably:

1. **ACT Targeting Results**: 
   - Higher prices for ACTs led to an increase in positivity among ACT recipients, particularly due to within-household selection where vouchers were allocated to likely malaria-positive individuals.
   - The most notable change was observed when the subsidy decreased from 92% to 88%, with the patient composition shifting from adults (who require a higher dose, thus more expensive) to children, despite the demographic of seekers not significantly changing.
   - At an 80% subsidy, the share of adult first voucher redemptions reduced by 16 percentage points, indicating price sensitivity among adults less likely to have malaria. 

2. **Mechanisms of Targeting**: 
   - Reduction in ACT subsidy levels caused a shift in purchases from adults to children, with adult redemptions falling by 41% between 92% and 80% subsidy levels.
   - Within age/dose groups, there was suggestive evidence of selecting higher-probability malaria cases when the subsidy was lower.

3. **Nonlinearity in Effects**: 
   - The greatest change in behavior and ACT targeting effect occurred between the 92% and 88% subsidy level, as these prices approached those of older antimalarial treatments.
   - Over-treatment remains a challenge, with 25% of ACTs at the lowest subsidy being purchased by malaria-negative individuals.

4. **Impact of RDT Subsidy**: 
   - The RDT subsidy did not significantly change where treatment was sought but increased the rate of malaria testing by 21.5%.
   - Despite this increase in testing, access to ACTs was not significantly affected overall by the introduction of an RDT subsidy.

The study concludes that while lower ACT prices increase the targeting efficacy by discouraging less positive adult cases, issues of over-treatment persist, emphasizing the need for better access to malaria diagnostics. The introduction of RDT subsidies improved testing rates but lacked impact on treatment-seeking behavior patterns, suggesting the value of diagnostics alone may not be sufficient to shift consumer behavior significantly.

The study explores the impact of rapid diagnostic test (RDT) subsidies on malaria treatment targeting in the context of varying antimalarial (ACT) subsidy levels. Key methodologies include stratifying households based on illness episodes, controlling for several demographic variables, and analyzing data from administrative records and surveys. The primary focus is on how RDT and ACT subsidies influence testing rates and treatment behaviors.

**Key Findings:**
1. **Malaria Testing Rates:** Providing an RDT subsidy significantly increased the likelihood of illness episodes being tested for malaria by 15–26 percentage points, effectively doubling testing rates compared to cases with no RDT. High redemption of RDT vouchers (about 80%) was noted even when there was a small fee involved.

2. **Impact on ACT and Antibiotic Usage:** Despite the increase in diagnostic testing, there was no significant change in the overall use of ACTs or antibiotics.

3. **ACT Targeting and RDTs:**
    - The RDT subsidy had limited impact on ACT targeting in households given subsidized ACT vouchers. 
    - No significant change was observed in the proportion of treatment seekers who were malaria-positive due to RDTs, suggesting minimal extensive margin effects.
    - However, there was an 8 percentage point increase in malaria positivity among those who took ACTs under the influence of the RDT subsidy, especially when the highest ACT subsidy level (92%) was provided.

4. **Compliance with RDT Results:** Compliance with negative test results was partial. Less than half of the individuals with a negative RDT result chose not to take ACTs, highlighting concerns about diagnostic trust and the potential for hoarding ACTs when subsidized heavily.

5. **Cost Effectiveness and Treatment Regimes:** The study uses its findings to simulate the effects of various subsidy schemes on under- and over-treatment. However, the detailed results of these simulations and specific cost-effectiveness conclusions are not included in the provided text.

6. **Sample and Data Details:** The study analyzed data from 1,993 observations, excluding any household members who were part of a surprise RDT without a subsidy. The results account for variability by including household and demographic controls.

**Conclusions:**
The research highlights the potential for RDT subsidies to increase malaria testing rates significantly. However, the impact on proper ACT targeting remains limited, primarily due to partial compliance with negative test outcomes. These findings suggest that while RDT availability enhances testing efforts, additional strategies are necessary to ensure improved targeting of ACTs. Future policies should consider these dynamics to enhance malaria treatment efficiency and reduce inappropriate ACT and antibiotic use.

The document analyzes the impact of an 80 percent subsidy on artemisinin-based combination therapies (ACTs) along with a subsidy for rapid diagnostic tests (RDTs) on malaria treatment. The study assesses access to ACTs, the targeting effectiveness at drug shops and health centers, and the issues of over- and under-treatment in malaria episodes.

Key Methodologies:
- The study uses experimental estimates to determine the total share of people taking ACTs and how well drug shops target appropriate treatment.
- Three assumptions for estimates of targeting at health centers (medium, high, and low) are examined.

Specific Metrics and Results:
- Total share taking ACT: Increased from 0.190 to 0.385 across different experimental setups.
- Share of ACTs taken at drug shops increased, while those at health centers decreased, improving targeting (up to 0.806 for drug shops).
- When assuming medium targeting at health centers, over-treatment was reduced from 0.048 to 0.129 and under-treatment was reduced significantly from 0.583 to 0.207.

Conclusions:
- The 80 percent ACT subsidy improved targeting and reduced both under- and over-treatment compared to no subsidy.
- Adding an RDT subsidy to the ACT subsidy did not prove cost-effective short-term but has potential long-term benefits by ensuring appropriate treatment for non-malaria illnesses, such as pneumonia.
- The subsidy is more cost-effective than the status quo (AMFm) and demonstrates potential in reducing costs while improving health outcomes.
- There is an indication that RDT compliance and social learning might improve over time, suggesting potential long-term benefits.

The welfare analysis finds that the 80 percent subsidy improves welfare by increasing the treatment of malaria-positive individuals with ACTs, though concerns about over-treatment affecting illnesses like bacterial infections remain. Further research is necessary to evaluate long-term impacts, especially regarding the external validity and broader geographical contexts.

The technical document discusses the evaluation of the Affordable Medicines Facility-malaria (AMFm) and its impact on antimalarial treatment access and usage, based on a study conducted in Kenya. The methodology involved surveys across rural areas, town centers, and small urban areas, focusing on the demand and targeting of Artemisinin-based Combination Therapies (ACTs). Key results and findings of the study include:

1. **Subsidy Effectiveness**: The ongoing public sector subsidy for ACTs has not fully achieved its aim to guarantee access for vulnerable populations due to a preference for drug shops over public health facilities in rural areas.

2. **Demand Sensitivity**: Demand for ACTs is low at unsubsidized prices but remains substantial and relatively inelastic across a range of subsidized prices, indicating the need for subsidies to increase access among rural, poorer populations.

3. **Over-treatment**: Over-treatment is prevalent, with only 45% of ACT recipients testing positive for malaria, a figure that aligns closely with an experimental estimate of 56% targeting under a 92% subsidy regime.

4. **Price as a Tool**: Higher ACT prices reduce unnecessary use among adults (less likely to suffer from malaria) while maintaining access for children.

5. **Diagnostic Testing Demand**: While demand for rapid diagnostic tests (RDTs) is high when affordable, compliance with test results must improve to enhance ACT targeting effectively.

The study concludes that while RDT provision and ACT subsidies are important, they are not sufficient on their own to solve the over-treatment issue. Households face challenges interpreting symptoms due to uncertainties in disease identification, ACT efficacy, and diagnostic accuracy. Future research is needed to explore how to encourage adherence to diagnostic outcomes and to refine provider incentives, addressing the complex incentive dynamics in malaria-endemic regions.

The documented research stresses the need for ongoing improvements and research in malaria subsidy policies, balancing access to effective treatment while minimizing misuse and resistance development.

The text appears to be a reference list from a technical or academic paper related to studies and reports on malaria, its treatment, and associated economic factors. Here is a summary capturing the methodologies, metrics, results, and conclusions indicated by the references:

1. Kangwana et al. (2009) reported on the shortage of malaria drugs in Kenya, suggesting a significant failure in providing effective malaria treatment access.
   
2. The Kenya Division of Malaria Control (2011) provided detailed malaria fact sheets highlighting various metrics around the disease’s impact and control strategies in the country.

3. Kremer et al. (2011) examined the effects of rural water impacts, value assessments, and property rights institutions in their paper published in the Quarterly Journal of Economics.

4. Leonard's studies (2007, 2009) focused on health outcomes by choosing better doctors, emphasizing social learning about doctor quality, especially in countries like Tanzania and Cameroon.

5. Leonard, Mliga, and Mariam (2002) explored the preferences for health center bypassing, providing insights into healthcare quality demand in Tanzania.

6. Marsh et al. (2004) researched improving malaria home treatment through drug retailer training in rural Kenya, revealing specific results regarding treatment efficacy.

7. Nichols and Zeckhauser (1982) and Olmstead and Zeckhauser (1999) discussed economic models and policies focused on targeting transfers and set pricing strategies in healthcare, applicable to drug formularies.

8. Oxfam (2012) and Patouillard et al. (2010) explored the impacts of the Affordable Medicine Facility and reviewed malaria treatment retail chains in developing regions.

9. Perkins and Bell (2008) emphasized the role of diagnostics in malaria control, while Punjabi et al. (2012) investigated the etiology of non-malaria febrile illnesses in Indonesia.

10. Shretta et al. (2000) used evidence to advocate for antimalarial drug policy changes in Kenya, while Smith et al. (2007) worked on standardizing Plasmodium falciparum parasite rates.

11. Tarozzi et al. (2014) conducted a randomized controlled trial in India assessing the impact of microloans and insecticide-treated bednets on malaria prevention.

12. Terlouw et al. (2003) reviewed issues related to sulfadoxine-pyrimethamine resistance and underdosing in Kenya, contributing to broader drug efficacy discussions.

13. White (2004) analyzed antimalarial drug resistance trends, providing critical insights into resistance's evolving nature.

14. WHO reports (2009, 2010, 2013) offered comprehensive malaria statistics and diagnostic test performance assessments, crucial for global malaria strategies and policy-making.

These references collectively highlight the complex challenges of malaria treatment, the role of economic policies, drug resistance, and the impact of healthcare infrastructure on treatment outcomes. The studies encourage evidence-based policy changes to improve malaria treatment accessibility and effectiveness significantly.

=== CODE RELATED FILES ===

=== DATASET FILES ===
=== END OF FILE CONTENT ===
2026-02-03 09:38:34,895 - replication - INFO - Updated metadata for extract_stage_1 in ./data/original/8/data-only/metadata.json
